Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

SAN JOSE, Calif.,/NEW YORK (Reuters) – A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.